DrugPatentWatch adds Paragraph IV newsfeed

March 9, 2011 - PRLog -- The addition of Paragraph IV Certification newsfeed enables pharmaceutical companies to track the generic companies challenging the patents of innovators through the Food and Drug Administration's 505(b) Paragraph IV Certification. This valuable data source complements existing indicators such as Paragraph IV challenges, patent claim types, and patent maintenance, reexamination, interference and disclaimer in providing a robust overview of the trends in pharmaceutical sales by branded and generic firms. The Paragraph IV Certification can go beyond information available from the FDA, indicating which generic companies have challenged branded pharmaceutical drug patents  -- this vital knowledge may aid investors in their decisions and help distributors and pharmacies plan their purchases.

Other datasets include:
- Impending drug patent expirations
- Annual sales
- Drug therapeutic class
- Paragraph IV challenges
- Premature patent expiration due to lack of maintenance fee payment
- Patent reexaminations
- Patent interferences
- Patent disclaimers
- Full-text drug patent PDFs
- Drug patent claim types (use, compound, formulation, etc.)

Detailed previews and a site tour are available at http://www.DrugPatentWatch.com

# # #

DrugPatentWatch provides comprehensive information on drug patents and their expirations.This value-added information supports patent agents and attorneys, pharmaceutical companies, wholesalers, healthcare payers, and investors.